Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SNS-101 |
Synonyms | |
Therapy Description |
SNS-101 is a monoclonal antibody that targets VSIR (VISTA; PD1H), which may lead to increase in tumor-infiltrating T-cells and enhanced antitumor immune response (Journal for ImmunoTherapy of Cancer 2022;10). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SNS-101 | SNS101|SNS 101 | VSIR Antibody 6 | SNS-101 is a monoclonal antibody that targets VSIR (VISTA; PD1H), which may lead to increase in tumor-infiltrating T-cells and enhanced antitumor immune response (Journal for ImmunoTherapy of Cancer 2022;10). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05864144 | Phase Ib/II | Cemiplimab + SNS-101 SNS-101 | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |